Furthermore, SIRPα-EVs treatment promoted dense infiltration of T cells in a syngeneic cancer mouse model, raising the possibility that CD47-targeted therapy could unleash innate and adaptive antitumor responses [31]. Here, CD47 is linked to cancer.